2012-09-18 08:04:41 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Astrocytoma - Pipeline Review, H2 2012', provides an overview of the Astrocytoma therapeutic pipeline. This report provides information on the therapeutic development for Astrocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Astrocytoma. 'Astrocytoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Full Report Details at

- www.fastmr.com/prod/463885_astrocytoma_pipeline_review_h2_2012.a ..


Scope

* A snapshot of the global therapeutic scenario for Astrocytoma.
* A review of the Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Astrocytoma pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Astrocytoma.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Astrocytoma pipeline depth and focus of Astrocytoma therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Astrocytoma Therapeutic Products under Development, Key Players in Astrocytoma Therapeutics, Astrocytoma Pipeline Overview, Astrocytoma Pipeline, Astrocytoma Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Astrocytoma Overview
Therapeutics Development
An Overview of Pipeline Products for Astrocytoma
Astrocytoma Therapeutics under Development by Companies
Astrocytoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Astrocytoma Therapeutics - Products under Development by Companies
Astrocytoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Astrocytoma Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Genentech, Inc.
MedImmune LLC
Merck & Co., Inc.
Lentigen Corporation
Sangamo BioSciences, Inc.
Plexxikon Inc.
Celltrion, Inc.
Ark Therapeutics Group plc
Novartis AG
Actelion Ltd
Eisai Co., Ltd.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Cell Therapeutics, Inc.
Exelixis, Inc.
Aduro BioTech
Merck KGaA
Novartis Pharmaceuticals Corporation
Celldex Therapeutics, Inc.
ImmunoCellular Therapeutics, Ltd.
Lixte Biotechnology Holdings, Inc.
Northwest Biotherapeutics, Inc.
Cleveland BioLabs, Inc.
Oncothyreon Inc
Peregrine Pharmaceuticals, Inc.
Pharmacyclics, Inc.
PhytoMedical Technologies, Inc.
Transgene SA
Prana Biotechnology Limited
Threshold Pharmaceuticals, Inc.
Proximagen Neuroscience plc.
Rexahn Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
Ambit Biosciences Corporation
Immupharma Plc
Adnexus Therapeutics, Inc.
immatics biotechnologies GmbH
Apogenix GmbH
Diffusion Pharmaceuticals LLC
MacroGenics, Inc.
Fina Biotech
Nobelpharma Co., Ltd.
Deciphera Pharmaceuticals, LLC
Vascular Biogenics Ltd.
Stemline Therapeutics, Inc.
BioCancell Therapeutics, Inc.
Axelar AB
Advenchen Laboratories, LLC
Viral Genetics, Inc.
Myriad Pharmaceuticals, Inc.
NOXXON Pharma AG
ChemoCentryx, Inc.
TVAX Biomedical, LLC
Sirnaomics, Inc.

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463885&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.